secwatch.observer — SEC 8-K summary
======================================

Issuer:     DarioHealth Corp. (DRIO)
CIK:        0001533998
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001104659-22-090461
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C
--------------------------------------------------------------------------------

- Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).
- Net loss $18.0M vs $17.8M in Q2 2021; operating loss $17.4M; cash $68M.
- B2B2C contract value totals $55M; new national health plan deal providing reach to ~10M members.
- Strategic decision to reduce DTC focus and prioritize B2B2C channels, cutting customer acquisition costs 70%.
- Secured up to $50M non-dilutive credit facility with OrbiMed; on track to exceed 100 B2B2C contracts by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/0001104659-22-090461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/tm2223436d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-090461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer